Cambridge Healthtech Institute’s 10th Annual

Antibodies for Cancer Therapy

Introducing and Optimizing Breakthrough Therapies

May 4-5, 2020


Antibodies have become the most sought-after tools in drug discovery, with bispecific antibodies and cell engagers leading the pack of new constructs. New insights on the tumor microenvironment and the microbiome can determine how successful a therapeutic strategy will be, and new imaging tools will help improve delivery of antibody drugs. The 10th Annual Antibodies for Cancer Therapy conference at PEGS will assemble an all-star roster of speakers to explore current results and learn best practices for moving molecules into the clinic.

Preliminary Agenda

IMPROVEMENTS IN TARGETING AND DELIVERY

Discovery and Clinical Translation of ONC201/TIC10

Wafik El-Deiry, MD, PhD, FACP, Associate Dean for Oncologic Sciences, Warren Alpert Medical School, Brown University

Optimization of Antibody Half-Life for Cancer Therapeutics

Donald J. Buchsbaum, PhD, Professor and Director, Division of Radiation Biology, Department of Radiation Oncology, University of Alabama at Birmingham

Selecting the Best Tumor Targets for Imaging

Cornelis F.M. Sier, PhD, Molecular Biologist, Project Leader Targeting, Department of Image-Guided Oncologic Surgery, Leiden University Medical Center

Bispecific Antibodies or TriKEs against a Variety of Solid Tumor Markers

Daniel A. Vallera, PhD, Lion Scholar and Professor, Director, Section on Molecular Cancer Therapeutics; University of Minnesota

Review of Targets and Drug Development Evolution

Arthur Frankel, MD, Chief, Hematology/Oncology, Mitchell Cancer Institute, University of South Alabama

BISPECIFIC ANTIBODIES AND IMMUNOTHERAPY COMBINATIONS

KEYNOTE PRESENTATION: Redirecting T-Cells for Cancer Immunotherapy Using Next-Generation Bispecific Antibodies and Fusion Proteins

Pablo Umaña, PhD, Head, Cancer Immunotherapy Discovery, Roche Innovation Center Zurich (Roche Glycart AG)

FEATURED PRESENTATION: Bispecifics and Beyond: Approaches for Identification of Effective Cancer Therapeutics

Andrew Nixon, PhD, Vice President, Biotherapeutics Molecule Discovery, Boehringer-Ingelheim Pharmaceuticals, Inc.

Assessing Immune Oncology Combinations with Common Light Chain Bispecific Antibodies

Simon Plyte, PhD, Vice President, Immune Oncology, Merus NV

Combinatorial Approaches to Enhance Bispecific Anti-Tumor Efficacy

Eric Smith, PhD, Senior Director, Bispecifics, Regeneron Pharmaceuticals, Inc.

BiSAb T-Cell Engagers that Target Tumor-Specific pMHC Antigens for Solid Tumors

G. Jonah Rainey, PhD, Vice President, Antibody Therapeutics, Gritstone Oncology

TARGETING B7/H3: BRINGING IT FORWARD TO CLINICAL APPLICATION

Talk Title to be Announced

Ezio Bonvini, MD, CSO & Senior Vice President, Research, MacroGenics, Inc.

Novel Approach to Target B7-H3

Soldano Ferrone, MD, PhD, Division of Surgical Oncology, Surgery, Massachusetts General Hospital

EMERGING TARGETS

BCMA-Directed CAR T Cells for Myeloma: What Have We Learned?

Adam D. Cohen, MD, Assistant Professor, Hematology & Oncology, Perelman Center for Advanced Medicine, University of Pennsylvania

CAR T Cells Targeting CD123 or Other Targets

Terry J. Fry, MD, Professor of Pediatrics, Hematology and Immunology, University of Colorado

Development of Cancer-Reactive Antibodies Focused to the 287-302 Amino Acid Loop of the Human Epidermal Growth Factor Receptor

David J. FitzGerald, PhD, Chief, Biotherapy Section, Laboratory of Molecular Biology, CCR, National Cancer Institute

Glypicans as Emerging CAR T Cell Therapy Targets: GPC3 and Beyond

Mitchell Ho, PhD, Chief, Antibody Therapy Section, Laboratory of Molecular Biology, National Cancer Institute, NIH



* The program is subject to change without notice, due to unforeseen reason.

Choose your language
Japanese
Traditional Chinese
Simplified Chinese
Korean


Update History
2019/11/25
Sponsor updated



View By: